Literature DB >> 21882214

Tumor focality is not associated with biochemical outcome after radical prostatectomy.

Viacheslav Iremashvili1, Liset Pelaez, Murugesan Manoharan, Kristell Acosta, Daniel L Rosenberg, Mark S Soloway.   

Abstract

BACKGROUND: The clinical and prognostic significance of unifocal prostatic carcinoma is not clearly understood. In the current study, we sought to characterize the clinical and pathologic characteristics of unifocal and multifocal prostate cancers and to investigate the effects of tumor focality on biochemical outcome after radical prostatectomy.
METHODS: Our analysis included 1,444 radical prostatectomy patients with available information concerning the number and location of tumor foci in the specimen. Each patient was assigned to one of three groups depending on whether they had unifocal, multifocal, or extensive cancer. Clinical and pathological features as well as biochemical outcomes were compared between the groups.
RESULTS: Two hundred and seventy-two mens in the study cohort (18.8%) had unifocal cancer. The rates of unifocal cancer did not differ significantly between the three studied time intervals (17.3% in 1992-1998, 20.5% in 1999-2004, and 17.8% in 2005-2011). The number of positive biopsy cores was slightly lower in the unifocal group, while the overall amount of biopsy tissue containing cancer was similar in both groups. The patients in the multifocal group had higher pathologic Gleason scores, increased incidence of positive surgical margin, and larger tumors. The rate of clinically significant Gleason score upgrade was significantly higher in the multifocal group compared to the unifocal group (35.7% vs. 21.7%, respectively, P < 0.001). The biochemical outcome after radical prostatectomy did not differ between patients with unifocal and multifocal cancers both on univariate and multivariate analyses.
CONCLUSIONS: Tumor focality is not an independent prognostic factor of biochemical outcome in radical prostatectomy patients.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21882214     DOI: 10.1002/pros.21481

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

Review 1.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

2.  Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology.

Authors:  Katsuhiro Ito; Akihiro Furuta; Akira Kido; Yuki Teramoto; Shusuke Akamatsu; Naoki Terada; Toshinari Yamasaki; Takahiro Inoue; Osamu Ogawa; Takashi Kobayashi
Journal:  Int J Clin Oncol       Date:  2019-12-02       Impact factor: 3.402

3.  Clinical features and prognosis of prostate cancer with high-grade prostatic intraepithelial neoplasia.

Authors:  Donghyun Lee; Chunwoo Lee; Taekmin Kwon; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2015-07-24

Review 4.  Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.

Authors:  Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Yuefang Jiang; Jun Yuan
Journal:  World J Surg Oncol       Date:  2018-07-03       Impact factor: 2.754

5.  Radical prostatectomy specimens - a voice against focal therapy.

Authors:  Przemysław Adamczyk; Jakub Tworkiewicz; Tomasz Drewa
Journal:  Cent European J Urol       Date:  2014-08-18

Review 6.  Multi-parametric magnetic resonance imaging as a management decision tool.

Authors:  David C Johnson; Robert E Reiter
Journal:  Transl Androl Urol       Date:  2017-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.